This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Controlled Trial

Samuel G. Siris, MD; Paul C. Bermanzohn, MD; Susan E. Mason, PhD; Mitchell A. Shuwall, PhD

Arch Gen Psychiatry. 1994;51(2):109-115.

Abstract
Background
Although recent studies have documented the benefit of adjunctive antidepressant medication for the short-term treatment of certain patients with operationally defined syndromes of postpsychotic depression, the value of maintenance adjunctive antidepressant treatment in this circumstance has not been properly established.

Methods
This study examined 24 schizophrenic or Schizoaffective patients with postpsychotic depression or negative symptoms. These patients had all been benefited over the short term by the addition of adjunctive imipramine hydrochloride to their ongoing fluphenazine decanoate/benztropine mesylate regimens, and this adjunctive treatment had been successfully continued for 6 months. In a randomized double-blind protocol, treatment with adjunctive imipramine hydrochloride (mean, 233 ± 72 mg/d) was then either maintained or tapered to placebo for an ensuing 1-year trial, while treatment with fluphenazine and benztropine continued.

Results
Significantly more patients who received placebo substitution relapsed into depression (P<.001). Patients who received placebo substitution were also more likely to experience relapses into psychosis (P<.02).

Conclusions
These results support the clinical value of maintenance adjunctive imipramine therapy among initially responsive patients with postpsychotic depressions.

Author Affiliations
From the Hillside Hospital Division of the Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, Glen Oaks, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial
Englisch et al.
J Psychopharmacol 2009;23:875-882.
ABSTRACT  

Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos et al.
Psychiatr. Serv. 2006;57:1094-1101.
ABSTRACT | FULL TEXT  

Patterns and Quality of Treatment for Patients With Schizophrenia in Routine Psychiatric Practice
West et al.
Psychiatr. Serv. 2005;56:283-291.
ABSTRACT | FULL TEXT  

Diagnosis and Treatment of Mood Disorders That Co-occur With Schizophrenia
Escamilla
Psychiatr. Serv. 2001;52:911-919.
ABSTRACT | FULL TEXT  

Suicide and schizophrenia
Siris
J Psychopharmacol 2001;15:127-135.
ABSTRACT  

Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
Siris
Am. J. Psychiatry 2000;157:1379-1389.
ABSTRACT | FULL TEXT  

Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
Millan et al.
J Psychopharmacol 2000;14:114-138.
ABSTRACT  

Treatment of Schizoaffective Disorder and Schizophrenia With Mood Symptoms
Levinson et al.
Am. J. Psychiatry 1999;156:1138-1148.
ABSTRACT | FULL TEXT  

Antidepressant Prescribing Practices of Outpatient Psychiatrists
Olfson et al.
Arch Gen Psychiatry 1998;55:310-316.
ABSTRACT | FULL TEXT  

Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty et al.
Arch Gen Psychiatry 1995;52:29-41.
ABSTRACT  

The Vicissitudes of Neurasthenia in Chinese Societies: Where Will It Go From the ICD-10?
Lee
Transcultural Psychiatry 1994;31:153-172.
ABSTRACT